The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease
Authors:
- Michael S. MegaMMMichael S. Mega
- Donna M. MastermanDMDonna M. Masterman
- Susan M. O'COnnorSOSusan M. O'COnnor
- Terry R. BarclayTBTerry R. Barclay
- Jeffrey L. CummingsJCJeffrey L. Cummings
Open Access
- 1 November 1999
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 56 (11) , 1388-1393
Abstract
CHOLINESTERASE inhibitor therapy in Alzheimer disease (AD) may provide cognitive1,2 and behavioral symptomatic improvement for some patients.3,4 Not all patients respond to cholinergic therapy; there is a response distribution from marked to no improvement.5 If significant cognitive response is measured by an improvement of at least 7 points on the cognitive portion of the Alzheimer's Disease Assessment Scale,6 then 26% of patients with AD may respond to cholinesterase inhibitor therapy (using donepezil hydrochloride) in 24 weeks of treatment.5Keywords
This publication has 12 references indexed in Scilit:
- Cerebral Blood Flow Correlates of Apathy in Alzheimer DiseaseArchives of Neurology, 1996
- Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label StudyJournal of Geriatric Psychiatry and Neurology, 1996
- The spectrum of behavioral changes in Alzheimer's diseaseNeurology, 1996
- Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomographyJournal of the Neurological Sciences, 1994
- Physostigmine ameliorates the delusions of Alzheimer's diseaseBiological Psychiatry, 1993
- Statistical Data Analysis in the Computer AgeScience, 1991
- Computer intensive statistical methodsEos, 1986
- A new rating scale for Alzheimer's diseaseAmerican Journal of Psychiatry, 1984
- Dementia: A Clinical Approach.Annals of Internal Medicine, 1984
- Reversible dementia. Illustrative cases, definition, and reviewJAMA, 1980